Syndax Pharmaceuticals Inc (SNDX) Stock: What the Analysts are Saying

The stock has a 36-month beta value of 0.94. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”

The public float for SNDX is 80.06M, and at present, short sellers hold a 12.53% of that float. On June 06, 2024, the average trading volume of SNDX was 1.05M shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

SNDX) stock’s latest price update

Syndax Pharmaceuticals Inc (NASDAQ: SNDX)’s stock price has soared by 2.07 in relation to previous closing price of 18.82. Nevertheless, the company has seen a loss of -2.59% in its stock price over the last five trading days. reported 2024-06-05 that WALTHAM, Mass., June 5, 2024 /PRNewswire/ — Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A.

SNDX’s Market Performance

Syndax Pharmaceuticals Inc (SNDX) has seen a -2.59% fall in stock performance for the week, with a -14.62% decline in the past month and a -19.12% plunge in the past quarter. The volatility ratio for the week is 4.02%, and the volatility levels for the past 30 days are at 4.33% for SNDX. The simple moving average for the past 20 days is -7.11% for SNDX’s stock, with a 0.21% simple moving average for the past 200 days.

Analysts’ Opinion of SNDX

Many brokerage firms have already submitted their reports for SNDX stocks, with Scotiabank repeating the rating for SNDX by listing it as a “Sector Perform.” The predicted price for SNDX in the upcoming period, according to Scotiabank is $23 based on the research report published on January 31, 2024 of the current year 2024.

Mizuho, on the other hand, stated in their research note that they expect to see SNDX reach a price target of $45. The rating they have provided for SNDX stocks is “Buy” according to the report published on December 22nd, 2023.

BofA Securities gave a rating of “Buy” to SNDX, setting the target price at $29 in the report published on October 25th of the previous year.

SNDX Trading at -10.46% from the 50-Day Moving Average

After a stumble in the market that brought SNDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.19% of loss for the given period.

Volatility was left at 4.33%, however, over the last 30 days, the volatility rate increased by 4.02%, as shares sank -17.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.39% lower at present.

During the last 5 trading sessions, SNDX fell by -2.59%, which changed the moving average for the period of 200-days by +8.04% in comparison to the 20-day moving average, which settled at $20.48. In addition, Syndax Pharmaceuticals Inc saw -11.11% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at SNDX starting from Morrison Briggs, who sale 52,855 shares at the price of $18.27 back on Aug 09 ’23. After this action, Morrison Briggs now owns 17,836 shares of Syndax Pharmaceuticals Inc, valued at $965,402 using the latest closing price.

Meury William, the Director of Syndax Pharmaceuticals Inc, sale 83,000 shares at $20.46 during a trade that took place back on Aug 02 ’23, which means that Meury William is holding 48,000 shares at $1,697,810 based on the most recent closing price.

Stock Fundamentals for SNDX

Current profitability levels for the company are sitting at:

  • -491.51 for the present operating margin
  • 0.21 for the gross margin

The net margin for Syndax Pharmaceuticals Inc stands at -448.94. The total capital return value is set at -0.54. Equity return is now at value -51.89, with -47.99 for asset returns.

Based on Syndax Pharmaceuticals Inc (SNDX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -147.64. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -3174.12.

Currently, EBITDA for the company is -229.94 million with net debt to EBITDA at 0.45. When we switch over and look at the enterprise to sales, we see a ratio of 2834.66. The receivables turnover for the company is 0.07for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.93.


To sum up, Syndax Pharmaceuticals Inc (SNDX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Most Popular

Related Posts